For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.

Over time, scar tissue slows or stops implanted bioelectronics. But new interdisciplinary research could help pacemakers, ...

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

In addition to the $1,500 grand prize, called the Lea Rudee Outstanding Poster Award, judges selected one student presenter ...

Metamorphx is emerging as a leading natural GLP-1 alternative for weight loss in 2025. With prescription options like ...

The NSF has awarded a Faculty Early Career Development Program grant to Jing Li, assistant professor of medical chemistry and ...

Semaglutide - the active ingredient in medications like Ozempic and WeGovy - is only FDA approved for Type-2 diabetes, but ...

Keeping up with the GLP-1 area is a full-time job by itself. First off, you have the recent development that these drugs are ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE phase 3 clinical trial published today in the New England Journal of Medicine ...

Ozempic, a popular drug for type 2 diabetes, has gained traction for its weight loss benefits, but it comes with potential ...